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MYC amplification in subtypes of breast
cancers in African American women
Tammey J. Naab1, Anita Gautam2, Luisel Ricks-Santi3, Ashwini K. Esnakula4, Yasmine M. Kanaan5,
Robert L. DeWitty6, Girmay Asgedom7, Khepher H. Makambi8, Massih Abawi9 and Jan K. Blancato10*
Abstract
Background: MYC overexpression is associated with poor prognosis in breast tumors (BCa). The objective of this study
was to determine the prevalence of MYC amplification and associated markers in BCa tumors from African American
(AA) women and determine the associations between MYC amplification and clinico-pathological characteristics.
Methods: We analyzed 70 cases of well characterized archival breast ductal carcinoma specimens from AA women for
MYC oncogene amplification. Utilizing immune histochemical analysis estrogen receptor (ER), progesterone receptor
(PR), and (HER2/neu), were assessed. Cases were Luminal A (ER or PR+, Ki-67 < 14%), Luminal B (ER or PR+, Ki-67 = >
14% or ER or PR+ HER2+), HER2 (ER-, PR-, HER2+), and Triple Negative (ER-, PR-, HER2-) with basal-like phenotype. The
relationship between MYC amplification and prognostic clinico-pathological characteristics was determined using chi
square and logistic regression modeling.
Results: Sixty-five (97%) of the tumors showed MYC gene amplification (MYC: CEP8 > 1). Statistically significant
associations were found between MYC amplification and HER2-amplified BCa, and Luminal B subtypes of BCa
(p < 0.0001), stage (p < 0.001), metastasis (p < 0.001), and positive lymph node status (p = 0.039). MYC amplification was
associated with HER2 status (p = 0.01) and tumor size (p = 0.01). High MYC amplification was seen in grade III
carcinomas (MYC: CEP8 = 2.42), pre-menopausal women (MYC: CEP8 = 2.49), PR-negative status (MYC: CEP8 = 2.42), and
ER-positive status (MYC: CEP8 = 2.4).
Conclusions: HER2 positive BCas in AA women are likely to exhibit MYC amplification. High amplification ratios
suggest that MYC drives HER2 amplification, especially in HER2 positive, Luminal B, and subtypes of BCa.
Keywords: MYC, FISH, Gene amplification, Breast cancer subtypes
Background
A significant racial disparity exists in the presentation and
outcome of breast cancer (BCa) between African American
(AA) women and non-Hispanic white women in the United
States. Despite the lower incidence of BCa among AAs
(124.3 vs 128.1 per 100,000), the death rate is higher in non-
Hispanic AA women (31.0 vs 21.9 per 100,000) [1]. Many
Biological and non-biological factors are thought to contrib-
ute to these disparities, including access to health care, socio-
economic factors, cultural issues, hormones, reproductive
influences, tumor characteristics, growth factors, cell cycle
proteins [2], tumor suppressor genes, and chromosomal
abnormalities [3, 4].
BCa is a heterogeneous disease consisting of different
genetic, cellular, and molecular subtypes, distinct biological
entities with unique clinical characteristics [5, 6]. On the
basis of intrinsic gene-based signatures using transcrip-
tional profiling, BCa has generally been subdivided into 4
major subtypes: luminal, HER2-enriched, basal-like, and
normal breast tumors. Many BCa with basal-like phenotype
tumors are ER negative, PR negative, and HER2 negative or
triple negative (TNBC) [5.6]. TNBC account for 10 to 20%
of all BCa cases and are more prevalent among AA, pre-
menopausal women and women with the BRCA1 muta-
tion. TNBCs tend to be aggressive tumors with poor
prognosis in part because no effective targeted therapies
have been identified for this BCa subtype [7].
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MYC, a multifunctional oncogene located on human
chromosome 8q24.21, has been shown to be amplified
and overexpressed in many types of human cancers, in-
cluding ovarian cancer, esophageal cancer, neuroblast-
oma, sarcoma, lung cancer, and BCas [8]. Depending
upon the type of malignancy, the frequency of alter-
ations in MYC varies between 1 and 94% at the crypto-
genic level [9]. In a meta-analysis of 29 studies of breast
ductal carcinomas, MYC amplification, defined as 2-fold
increase in gene copy number, was found in approxi-
mately 16% of cases [10]. Amplification of MYC is asso-
ciated with poor prognosis, high-grade BCas, and early
relapse [11, 12].
Identified as a downstream target of HER2, MYC activates
various kinase-signaling pathways that may be regulated by
ER or PR [13–15]. Many studies have shown that MYC-
amplified BCas also harbor HER2 amplification, suggesting
a co-amplification [16]. These studies demonstrate that co-
amplification of MYC and HER2 augments the development
of aggressive tumors with enhanced self-renewal and tumor
propagating characteristics. Nevertheless, the underlying
mechanism of the interaction between HER2 and MYC that
contributes to mammary oncogenesis remains poorly under-
stood [17].
In light of the above, we analyzed a series of well character-
ized archival invasive ductal carcinoma specimens in order to
better understand which BCa subtypes are more likely to be
driven by MYC with potential co-amplification of HER2. The
objective of the study was to determine the prevalence of
MYC amplification in BCa tumors from African American
(AA) women and determine the association between MYC
amplification and BCa clinic-pathological characteristics.
Methods
Specimen acquisition
This retrospective study was based on anonymized,
formalin-fixed, paraffin-embedded FFPE archival BCa tis-
sues (e.g. triple negative BCa, Luminal A, Luminal B, and
HER2 positive) were obtained from Howard University
Hospital Department of Pathology in Washington, DC.
They were collected over a ten year period of time ranging
from 2000 to 2010. IRB approval for the conduct of this
study was received from Howard University’s Institutional
Review Board and designated as exempt 15CMED-53. A
total of 70 samples were analyzed. Samples were selected
based on the availability and adequacy of FFPE tissue
blocks for further study. Five μm thick sections were cut
and areas of well-preserved carcinoma in a Hematoxylin
and Eosin (H&E) orienting slide from each block were
marked for study through hybridization and microscopy.
Demographic and clinic-pathological data were obtained
through the Howard University Cancer Center Tumor
Registry.
Fluorescence in situ hybridization (FISH)
Fluorescence in situ hybridization (FISH) techniques were
used to assess MYC amplification in tumor specimens as
previously described in our previous study (18). Briefly,
the orange fluorophore directly-labeled MYC probe
(CymoGen DX, NY USA) and a green labeled centromere
8 probe (Empire Genomics, NY, USA) were used to make
a FISH probe mix. The slides were then baked overnight
at 60 °C to adhere the tissues to the slides. Slides were
subsequently deparaffinized by consecutive 10-min xylene
washes before being rehydrated through 100% ethanol in-
cubation for 10 min at room temperature. The tissue on
the slides were then permeabilized and digested using the
Abbott (Naperville, IL) tissue digestion kit containing pep-
sin, according to manufacturer’s instruction. The sections
were washed with wash buffer after consecutive pretreat-
ment and protease digestion. The probe was denatured at
74 °C for 10 min and immediately transferred to an ice
bucket. The denatured probe was then added to the
marked area on the slides and was sealed with rubber ce-
ment. The slides and the probe were co-denatured for
8 min in HYBrite heat plate (Vysis, Naperville, Illinois) at
85 °C for 8 min and then incubated for 16 to 24 h at 37 °
C. Coverslips were removed and the slides were Post
Washed in 2X SSC hybridization buffer for 2 min at 73 °C
and transferred to 2X SSC at room temperature for 5 min.
The slides were air dried in the dark for 1 h in an upright
position. Lastly, the slides were counterstained with DAPI
(4′, 6-diamidino-2-phenylindole) from Sigma Aldrich and
were viewed with a Zeiss Axioscope fluorescence micro-
scope and imaged with Applied Imaging (Pittsburgh, PA)
Cytovision software.
Signal enumeration
FISH images were acquired using a Zeiss Axioscope fluor-
escence microscope equipped with a camera and multiple
fluorescence filter sets with three color filter set DAPI,
FITC and TRITC. The slides were screened with 100× oil
objective lens through the DAPI filter to determine the
cell area by observing the area of interest marked by the
Pathologist. The centromeres were counted as green sig-
nals whereas the MYC signals were viewed as orange sig-
nals with the TRITC filter (Fig. 1). At least 50 cells were
enumerated from a single slide when possible. The signal
ratio of the centromere to MYC in normal cells was calcu-
lated. The normal control was 2:2; an increase in the ratio
was considered abnormal or amplified. The results were
expressed as number of MYC signals/number of chromo-
some 8 signals (MYC: CEP8) [18].
Statistical methods
The statistical analysis software, IBM SPSS Statistics for
Windows(Version 22. Armonk, NY: IBM Corp) was used
to perform descriptive analysis of clinic-pathological
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variables and determine the association between MYC
amplification (dependent variable) and prognostic clinic-
pathological characteristics such as ER, PR, and HER2
positivity, molecular BCa subtype, stage, grade, and tumor
size (independent variables). The Chi-square (χ2) test or T
test, as appropriate, was used to examine bivariate associ-
ation between MYC-amplification, CK 5/6 expression and
clinic-pathologic variables. Age was categorized into two
groups with a cutoff of 50 years. The logistic regression
analysis or ANOVA, as appropriate, was used to examine
independent association between MYC amplification and
clinic-pathological variables. Results were reported as odds
ratios (OR) along with calculated 95% confidence intervals
(CI). Pearson’s correlation was used to determine the cor-
relation between amplification ratio, tumor size, and age of
diagnosis.. Kaplan-Meier (K-M) estimate of overall survival




Clinicopathological characteristics of the study population
are summarized in Table 1. Seventy paraffin-embedded
archival tissues of BCa were studied. The average age at
diagnosis was 56 years with a minimum and maximum age
of 29 and 85 years, respectively. Approximately 37% of the
cases were TNBCs; HER2-amplified tumors comprised
11.4% of the tumors in this study; and Luminal A and
Luminal B tumors comprised 30% and 21% of the tumors,
respectively. ER, PR, and HER2 were positive in 50%,
45.7%, and 18.6% of tumors, respectively. Most of the
tumors were poorly differentiated (74%). The frequency of
stage I, II, II, and IV tumors were 23.4%, 41.4%, 22.9%, and
5.7%, respectively.
FISH analysis of gene amplifications and BCa subtypes
Figure 1 demonstrates representative FISH images with
a red labeled MYC probe and a green labeled chromo-
some 8 centromere probe. Normal, intermediate, and
high MYC amplification tissues for these studies are pre-
sented. The normal MYC: CEP8 ratio is 1. The average
MYC amplification ratio was 2.25. Thirty-six percent of
the cases had high amplification ratio (MYC: CEP 8
ratio > 2). High MYC amplification scores were observed
in HER2 (3.97 ± 1.99) and Luminal B (3.34 ± 2.11) sub-
types, whereas low amplification was seen in TNBC
(1.65 ± 0.94) and Luminal A (1.65 ± 0.93) subtypes as
shown in Table 2. The mean MYC amplification ratio of
HER2, Luminal A, and TNBC differ significantly; how-
ever, HER2 and Luminal B do not significantly differ
from each other (p < 0.001).
a b
c d
Fig. 1 FISH hybridization of MYC in breast tumor tissues. The FISH probe for MYC is labeled with a red fluorochrome, and the normal control
signal for the chromosome 8 centromere is labeled in green. The nuclei of the cells are visualized via DAPI counterstaining. a 1:3 ratio of MYC to
centromere signals indicating low amplification is shown. b 1:5 ration of MYC to centromere signals indicating moderate amplification is shown.
c 1:1 copy ratio of MYC to centromere signals indicating no amplification of the MYC gene is shown. d 1: 8 copy ratio of MYC to centromere
signals indicating high amplification is shown in the panel
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MYC amplification and HER2/PR/ER status
In all, 20% of the samples were HER2 positive (13% HER2
subtype, 7% Luminal B). The average MYC amplification
ratio for HER2 positive BCas was 4.36 (±2.24) and 1.77
(±0.97) for HER2 negative/not amplified BCa cases as pre-
sented in Table 3. The mean difference between Her2 +
and Her2- tumors was statistically highly significant with
p = < 0.001 as detailed in Table 3. Average MYC amplifica-
tion scores did not differ significantly between ER+ and
ER-, as well as PR+ and PR- tumors. Regression analysis
also revealed an association between the HER2+ subtype
(OR = 29.75 95% CI: 2.80–315.56; p < 0.0001) and Luminal
B HER2 positive subtype (OR = 10.63 95% CI 2.16–52.15;
p < 0.0001), as well as with HER2 immuno-histochemical
expression (OR = 40.62 95% CI 4.82–342.39; p < 0.00001).
However, no statistically significant association was found
between MYC amplification and cancer grade, origin of
tumor, tumor size, or age of diagnosis.
BCa survival analysis and BCa subtypes
In addition, Table 4 shows the survival analysis data in
relation to MYC amplification and clinic-pathological
variables. Statistically significant differences in overall
survival were found when stratifying by stage (p < 0.001),
having metastatic disease (p < 0.001), and lymph node
positivity (p = 0.039). However, no statistically significant
difference in overall survival was observed among BCa
subtypes in this study (Log rank test p = 0.201). The
mean overall survival was 71.00 months for HER2 sub-
type (95% CI = 44.09–97.91), 94 months (95% CI =
84.56–103.44) for Luminal B, 67.71 months (95% CI =
52.05–83.36) for Luminal A, and 100.07 months (95%
CI = 76.57–123.57) for TNBC subtype.
Table 5 demonstrates that differences in mean survival
were not found when stratifying by MYC amplification
(p = 0.265). .
Discussion
An association between MYC amplification and HER2
overexpressing tumors in AAs was found in this pilot
study of AA patients. Importantly, cases of Luminal B
with positive HER2 expression exhibited the highest
MYC amplification ratios. Specifically, HER2/neu recep-
tor positive cases had 4.5 more copies of MYC than
HER2/neu negative cases, a difference that suggests a
significant association between MYC amplification and
hormone receptor positivity in HER2 positive Luminal B
BCas (p = 0.01). Luminal A HER2 positive BCas did not
demonstrate high MYC amplification. We did not ob-
serve any association between MYC amplification and
tumor grade, tumor size, or age at diagnosis similar to
other studies [18–20].
Table 1 Demographic and clinico-pathological characteristics of
cases
Characteristics Mean Range
Age of Diagnosis (Years)
56.36 years 29–85 years




Luminal A 21 30
Luminal B 15 21.4
Luminal B (Ki-67≥ 14%) 9 12.9
Luminal B HER2+ 6 8.6
















Grade I: Well differentiated 1 1.4
Grade II: Moderately differentiated 15 21.4
Grade III: Poorly differentiated 52 74.3
Table 2 C-MYC Amplification in various breast cancer subtypes
Breast Cancer Subtype Frequency Mean Standard Deviation Min Max Tukey Grouping
HER2 8 3.63 2.27 1.16 7.08 A
Luminal A 21 1.65 2.12 0.94 4.7 B
Luminal B 15 3.19 0.67 1.00 9.28 A
Triple negative 26 1.52 2.27 0.76 3.56 B
ANOVA F-test =8.52; p < 0.0001 A = 0.625 B = 1.00
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In BCas, amplification of MYC is associated with poor
prognosis, high-grade, and early relapse [11–13]. The dis-
tribution of MYC amplification varies by BCa subtypes
and MYC amplification has been shown to be associated
with BCa molecular subtypes and hormonal receptor sta-
tus. High MYC amplification (MYC: CEP8 ratio > 2) has
been reported in HER2 and Luminal B subtypes of BCa
whereas low MYC amplification scores were observed in
Luminal A and TNBC subtypes [19, 20]. Another study
showed high MYC amplification in TNBCs, particularly
incases demonstrating a basal-like phenotype [21–23].
The majority of analyses have shown that MYC-
amplified BCas also harbor HER2 amplification, suggest-
ing a co-amplification mechanism (16). Consistent with
these studies, we also demonstrated that HER2 positive
BCas in this population of AA women were more likely to
exhibit MYC amplification. High amplification ratios may
suggest that increases in MYC activity drives HER2 ampli-
fication, especially in HER2 positive and Luminal B
HER2-amplified subtypes of BCa. Therefore, MYC may
play a significant role in steroid receptor dependent as
well as independent tumorigenesis.
This study shows low MYC amplification scores in Lu-
minal A and TNBCs. Another recent study measured
MYC gene copy number in 94 breast tumors of all sub-
types with semi-quantitative multiplex PCR. They did not
find any association of amplification with age, tumor size,
ER and PR status, local metastases, or histologic grading,
but noted that MYC amplification was present in early tu-
mors but not adjacent normal tissues [11]. Laboratory test
systems, FISH probe choices, and microscopy factors
affect study sensitivity, particularly with low levels of amp-
lification which may not be resolved adequately.
To further explore the relationship between MYC
amplification and steroid receptor status, we evaluated
the association between MYC: CEP8 ratio and the pres-
ence/absence of PR and ER. Our study yielded mixed re-
sults consistent with those obtained in previous studies
[15, 24]. The mean MYC amplification ratio in PR nega-
tive tumors was 0.5 times higher than in tumor tissues
that were PR positive; ER positive cases had slightly
higher MYC amplification ratios than ER negative cases.
However, there was no significant relationship between
the PR/ ER receptor status and MYC amplification (p =
0.50, 0.57, respectively). Notably, the MYC amplification
score was high in tumors that metastasized to brain or
bone. Although the precise nature of the ER and PR sig-
naling pathway and its relationship with MYC amplifica-
tion remain unclear, PR was reported to influence
proliferation and cell differentiation, and to exhibit a bi-
phasic effect on cell growth and MYC expression [25]. A
more recent study conducted by Wang et al. indicated
Table 3 MYC amplification with ER, PR and HER2
Characteristic N Mean Std Dev Minimum Maximum p-value
ER
Negative 35 2.18 1.57 0.76 7.08
Positive 35 2.33 1.71 0.94 9.28 0.71
PR
Negative 38 2.47 1.94 0.76 9.28
Positive 32 1.99 1.14 0.94 5.50 0.23
HER2
Negative 57 1.77 0.97 0.76 5.00
Positive 13 4.36 2.24 1.28 9.28 < 0.001
Table 4 Regression analysis of MYC expression and clinico-pathological variables
C-MYC Amplification Odds 95% CI
< 2 > 2 Ratio Lower Upper p-value
Breast Cancer Molecular Subtype
Luminal A 17 81.0% 4 19.0% ref.
Luminal B 4 28.6% 10 71.4% 10.63 2.16 52.15 < 0.0001
HER 2+ 1 12.5% 7 87.5% 29.75 2.80 315.56 < 0.0001
Triple Negative Breast Cancer 23 85.2% 4 14.8% 0.74 0.16 3.38 0.72
Estrogen Receptor Status
Positive 21 60.0% 14 40.0% ref.
Negative 24 68.6% 11 31.4% 0.69 0.26 1.84 0.31
Progesterone Receptor Status
Positive 21 65.6% 11 34.4% ref.
Negative 24 63.2% 14 36.8% 1.11 0.42 2.98 0.52
HER2 Status
Negative 44 77.2% 13 22.8% ref.
Positive 1 7.7% 12 92.3% 40.62 4.82 342.39 < 0.0001
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that MYC expression could be induced by estrogen, in-
volving the integration of MYC between ER and AP-1 at
the distal enhancer element suggesting that AP-1 may
play a role in induction of the MYC oncogene [26].
Future studies to investigate the role of MYC as a
downstream mediator of HER2 may assist in under-
standing the role MYC gene on growth regulatory genes
in different BCa subtypes. Also, studies evaluating differ-
ences in MYC amplification between primary breast tu-
mors and metastatic sites in bone, lung, and brain would
be useful to determine whether lethality of metastatic
disease is related to MYC amplification, especially in mi-
nority populations.
Conclusion
We demonstrate that HER2+ breast cancer tissues from
AA women that demonstrate also have a high likelihood
to show MYC amplification. High amplification ratios
suggest that MYC drives HER2 amplification, especially
in HER2 positive BCas including both the HER2 subtype
and HER2 + Luminal B subtype. This provides support
the concept that MYC plays a part on steroid dependent
and independent tumor development.
Abbreviations
AA: African American; ANOVA: Analysis of Variants; BCa: Breast cancer;
CEP: Centromere Enumeration Probe; CI: Confidence Interval; DAPI: 4′,6-
diamidino-2-phenylindole; ER: Estrogen Receptor; FFPE: Formalin fixed
paraffin embedded; FISH: Fluorescence in situ Hybridization; FITC: Fluorescein
isothiocyanate; H & E: Hematoxylin and Eosin; HER2/neu: Receptor tyrosine-
protein kinase erbB-2; IRB: Institutional Review Board; MYC: c-Myc gene;
OR: Odds Ratio; PR: Progesterone Receptor; TNBC: Triple Negative Breast
Cancer; TRITC: Tetramethylrhodamine
Acknowledgements
We thank Will Mumford for his assistance with manuscript preparation.
Funding
The MYC probe used in this study was generously supplied by CymoGenDx,
New York, USA. Partial funding for AG was provided by a Susan Komen
Foundation grant Graduate Training in Breast Cancer Disparities at Lombardi
Cancer Center (GTDR15330383).
Availability of data and materials
The datasets and selected material analyzed in the current study are
available from the corresponding author upon reasonable request.
Author’s contributions
Study idea, design, and workflow supervision: JKB, AEK, RD and TN. Laboratory
analysis: AG, MA, LRS, YK, RD and JKB. Data analysis and interpretation: KM, AEK,
LSR, and GA. Technical assistance in manuscript preparation: TN, LRS, and JKB.
All authors read and approved the final manuscript.
Table 5 Survival analysis of clinico-pathological variables and MYC amplification
95% CI
Mean Months Std. Error Lower Bound Upper Bound p-value
Stage
1 119.59 9.62 100.73 138.45
2 92.03 7.75 76.85 107.21
3 98.25 15.12 68.61 127.89
4 18.25 6.02 6.45 30.05 p < 0.001
Size (T)
T1 89.35 4.53 80.47 98.23
T2 100.60 9.98 81.04 120.17
T3 82.50 16.74 49.69 115.32 p = 0.06
Distant Metastases
No Metastatic Disease (0) 114.88 7.06 101.05 128.71
Metastatic Disease (1) 38.78 13.97 11.40 66.16 p < 0.001
Lymph Nodes
Lymph Node Negative (0) 124.65 8.29 108.40 140.90
Lymph Node Positive (1) 86.88 10.33 66.64 107.11 p = 0.039
Breast Cancer Molecular Subtype
Luminal A 67.71 7.99 52.05 83.36
Luminal B 94.00 4.82 84.56 103.44
HER 2+ 71.00 13.73 44.09 97.91
Triple Negative Breast Cancer 100.07 11.99 76.57 123.57 p = 0.201
C-MYC Amplification
< 2 93.96 8.96 76.41 111.52
> 2 117.03 9.98 97.47 136.59 p = 0.265
Naab et al. BMC Cancer  (2018) 18:274 Page 6 of 7
Ethics approval and consent to participate
This study was based on existing de-identified data and pathologic specimens.
It was not deemed to be human subjects’ research, but determined to be of
exempt status. Approval for this research protocol was given by the Howard
University School of Medicine IRB, designated as reference number 15CMED-53.
Consent for publication
Subject consent was not required for this study. It is bound by the ruling of the US
Health and Human Services Secretary’s Advisory Committee on Human Research
Protections (SACHRP) under the Common Rule for exempt research and the Helsinki
guidelines for establishment of IRB committees. IRB approval #15C MED 53 was
obtained from the Howard University IRB for the study of de-identified materials.
Competing interests
The authors declare that they have no competing interests.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Author details
1Department of Pathology, Howard University College of Medicine, Howard
University Hospital, 2041 Georgia Avenue Rm. 1M-06, Washington DC, NW
20060, USA. 2Department of Oncology, University of Massachusetts Medical
School, 373 Plantation street Suite# 318, Worcester, MA 01581, England.
3Cancer Research Center, Department of Biological Sciences, Hampton
University, 100 E. Queen Street, Hampton, VA 23668, USA. 4Department of
Pathology, Immunology and Laboratory Medicine, University of Florida
College of Medicine, P.O. Box 100275, 1600 SW Archer Road, Gainesville, FL
32610-0275, USA. 5Department of Microbiology, Howard University College
of Medicine, 2041 Georgia Avenue Rm. 1M-06, Washington DC, NW 20060,
USA. 6Department of Surgery, Howard University Hospital, 2041 Georgia
Avenue, Washington DC, NW 20060, USA. 7Department of Medicine, Howard
University Hospital, 2041 Georgia Avenue, Washington DC, NW 20060, USA.
8Department of Biostatistics, Bioinformatics, and Biomathematics, Lombardi
Comprehensive Cancer Center, Georgetown University, 4000 Reservoir Road,
Washington, DC, NW 20057, USA. 9Inherited Cancer Program, GeneDx, 207
Perry Pkwy, Gaithersburg, MD 20877, USA. 10Department of Oncology,
Lombardi Comprehensive Cancer Centre, Georgetown University Medical
Centre, 3800 Reservoir Road, Washington DC, NW 20007, USA.
Received: 22 May 2017 Accepted: 26 February 2018
References
1. Copeland G LA, Firth R, et al. Cancer in North America: 2008–2012. North
American Association of Central Cancer Registries, Inc, Springfield, IL. June
2015.;Volume One: Combined Cancer Incidence for the United States,
Canada and North America.
2. Lund MJ, Trivers KF, Porter PL, et al. Race and triple negative threats to
breast cancer survival: a population-based study in Atlanta, GA. Breast
Cancer Res Treat. 2009 Jan;113(2):357–70.
3. Loo LW, Wang Y, Flynn EM, et al. Genome-wide copy number alterations in
subtypes of invasive breast cancers in young white and African American
women. Breast Cancer Res Treat. 2011 May;127(1):297–308.
4. Danforth DN Jr. Disparities in breast cancer outcomes between Caucasian
and African American women: a model for describing the relationship of
biological and nonbiological factors. Breast Cancer Res. 2013;15(3):208.
5. Parker JS, Mullins M, Cheang MC, et al. Supervised risk predictor of breast
cancer based on intrinsic subtypes. J Clin Oncol. 2009 Mar 10;27(8):1160–7.
6. Sorlie T, Tibshirani R, Parker J, et al. Repeated observation of breast tumor
subtypes in independent gene expression data sets. Proc Natl Acad Sci U S
A. 2003 Jul 8;100(14):8418–23.
7. Perou CM. Molecular stratification of triple-negative breast cancers.
Oncologist. 2011;16(Suppl 1):61–70.
8. Dang CVMYC. On the path to cancer. Cell. 2012 Mar 30;149(1):22–35.
9. Liao DJ, Dickson RB. C-Myc in breast cancer. Endocr Relat Cancer. 2000 Sep;
7(3):143–64.
10. Deming SL, Nass SJ, Dickson RB, et al. C-myc amplification in breast cancer:
a meta-analysis of its occurrence and prognostic relevance. Br J Cancer.
2000 Dec;83(12):1688–95.
11. Chrzan P, Skokowski J, Karmolinski A, et al. Amplification of c-myc gene and
overexpression of c-Myc protein in breast cancer and adjacent non-
neoplastic tissue. Clin Biochem. 2001 Oct;34(7):557–62.
12. Blancato J, Singh B, Liu A, et al. Correlation of amplification and overexpression
of the c-myc oncogene in high-grade breast cancer: FISH, in situ hybridisation
and immunohistochemical analyses. Br J Cancer. 2004 Apr 19;90(8):1612–9.
13. Bouchalova K, Cizkova M, Cwiertka K, et al. Triple negative breast cancer–
current status and prospective targeted treatment based on HER1 (EGFR),
TOP2A and C-MYC gene assessment. Biomed Pap Med Fac Univ Palacky
Olomouc Czech Repub. 2009 Mar;153(1):13–7.
14. Hynes NE, Myc LHA. Mammary cancer: Myc is a downstream effector of the
ErbB2 receptor tyrosine kinase. J Mammary Gland Biol Neoplasia. 2001 Jan;
6(1):141–50.
15. Todorovic-Rakovic N, Neskovic-Konstantinovic Z, Nikolic-Vukosavljevic D. C-
myc as a predictive marker for chemotherapy in metastatic breast cancer.
Clin Exp Med. 2012 Dec;12(4):217–23.
16. Park K, Kwak K, Kim J, et al. C-myc amplification is associated with HER2
amplification and closely linked with cell proliferation in tissue microarray of
nonselected breast cancers. Hum Pathol. 2005 Jun;36(6):634–9.
17. Nair R, Roden DL, Teo WS, et al. C-Myc and Her2 cooperate to drive a stem-
like phenotype with poor prognosis in breast cancer. Oncogene. 2014 Jul
24;33(30):3992–4002.
18. Blancato JK, Williams MS, Dickson RB. Fluorescence in situ hybridization
assessment of c-myc gene amplification in breast tumor tissues. Methods
Mol Med. 2006;120:297–307.
19. Li C, Bai J, Hao X, et al. Multi-gene fluorescence in situ hybridization to
detect cell cycle gene copy number aberrations in young breast cancer
patients. Cell Cycle. 2014 Apr 15;13(8):1299–305.
20. Yasojima H, Shimomura A, Naoi Y, et al. Association between c-myc
amplification and pathological complete response to neoadjuvant
chemotherapy in breast cancer. Eur J Cancer. 2011 Aug;47(12):1779–88.
21. Horiuchi D, Kusdra L, Huskey NE, et al. MYC pathway activation in triple-
negative breast cancer is synthetic lethal with CDK inhibition. J Exp Med.
2012 Apr 9;209(4):679–96.
22. Singhi AD, Cimino-Mathews A, Jenkins RB, et al. MYC gene amplification is
often acquired in lethal distant breast cancer metastases of unamplified
primary tumors. Mod Pathol. 2012 Mar;25(3):378–87.
23. Alles MC, Gardiner-Garden M, Nott DJ, et al. Meta-analysis and gene set
enrichment relative to er status reveal elevated activity of MYC and E2F in
the "basal" breast cancer subgroup. PLoS One. 2009;4(3):e4710.
24. Perez EA, Jenkins RB, Dueck AC, et al. C-MYC alterations and association
with patient outcome in early-stage HER2-positive breast cancer from the
north central cancer treatment group N9831 adjuvant trastuzumab trial. J
Clin Oncol. 2011 Feb 20;29(6):651–9.
25. Wong MS, Murphy LC. Differential regulation of c-myc by progestins and
antiestrogens in T-47D human breast cancer cells. J Steroid Biochem Mol
Biol. 1991 Jul;39(1):39–44.
26. Wang C, Mayer JA, Mazumdar A, et al. Estrogen induces c-myc gene
expression via an upstream enhancer activated by the estrogen receptor
and the AP-1 transcription factor. Mol Endocrinol. 2011 Sep;25(9):1527–38.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Naab et al. BMC Cancer  (2018) 18:274 Page 7 of 7
